Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms Anti-CD22 monoclonal antibody LL2-I-131, Monoclonal antibody LL2-I-131, IMMU LL2-I-131 + [2] |
Target |
Action modulators |
Mechanism CD22 modulators(CD22 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Phase 2 | United States | - | - |
Non-Hodgkin Lymphoma | Phase 2 | - | - | |
Non-Hodgkin Lymphoma | Phase 2 | - | - |